摘要
目的 评价芪胶升白胶囊治疗肺癌放疗期间白细胞抑制的效果.方法 回顾性分析2011年10月至2012年10月在浙江省台州医院放射治疗科接受序贯放化疗或放化同步治疗50例肺癌患者的临床资料,根据是否口服芪胶升白胶囊分为观察组（放疗期间口服芪胶升白胶囊,25例）和对照组（服用安慰剂25例）,对比2组患者的骨髓抑制程度、白细胞下降率和白细胞下降最严重时间.结果 观察组的骨髓抑制程度明显低于对照组,差异均有统计学意义（P＜0.05）;观察组白细胞数下降率明显低于对照组[序贯放化疗：（21±11）％比（37±18）％;同步放化疗：（52±20）％比（72±24）％],差异均有统计学意义（均P＜0.05）;白细胞数下降最严重时间明显长未对照组[序贯放化疗：（23.3±4.3）d比（20.2±4.4）d;同步放化疗：（18.6±3.8）d比（14.7±2.7）d],差异具有统计学意义（均P ＜0.05）.结论 肺癌放疗期间应用芪胶升白胶囊对白细胞抑制有确切的改善作用.
Objective To explore the effect of Qijiao Shengbai capsules on white blood cells suppression during efficacy of radiotherapy for lung cancer.Methods The clinical data of 50 cases of patients with lung cancer accepted sequential chemotherapy or chemoradiotherapy resynchronization therapy was retrospectively analyzed.All 50 patients were divided into observation group （oral Qijiao Shengbai capsules,25 cases） and control group （without oral Qijiao Shengbai capsules,25 cases）.The inhibition of leukocyte contrast level and the lowest rate of leukopenia and neutropenia between the two groups were all compared.Results The degree of bone marrow suppression in the observation group was significantly lower than that in the control group （P 〈 0.05）.White blood cell count decreasing rate in observation group was significantly lower than that in the control group [sequential chemoradiotherapy：（21 ± 11） % vs （37 ± 18） % ; concurrent chemoradiotherapy：（52 ± 20） % vs （72 ± 24） %]（P 〈 0.05）.Leukopenia worst time in observation group was significantly longer than the control group [sequential chemoradiotherapy：（23.3 ± 4.3） d vs （20.2 ± 4.4） d ; concurrent chemoradiotherapy：（18.6 ± 3.8） % vs （14.7 ± 2.7） %],the difference was statistically significant （P 〈 0.05）.Conclusion Qijiao shengbai radiotherapy for lung cancer can significantly improve the leukocyte inhibition.
出处
《中国医药》
2014年第2期176-178,共3页
China Medicine
基金
恩泽医疗中心（集团）科学研究基金（11EZC12）
关键词
肺癌
芪胶升白胶囊
放化疗
Lung cancer
Qijiao Shengbai capsules
Chemotherapy and radiotherapy
